ARTICLE | Company News
IMMU receives payment from Amgen
February 1, 2001 8:00 AM UTC
Immunomedics (IMMU) received an $18 million upfront payment from partner AMGN under the companies' December deal for AMGN to develop and market in North America and Australia IMMU's epratuzumab humani...